Skip to main content
Premium Trial:

Request an Annual Quote

Freenome Nets $290M Investment From Roche

NEW YORK – Freenome said Tuesday that Roche has made an investment of $290 million in its company, bringing its total funding to more than $1.1 billion since the firm was founded in 2014.

Freenome's lead diagnostic product is a blood-based early detection test for colorectal cancer, but the firm has maintained that it plans to eventually expand to multiple other tumor types. The new investment from Roche, along with $300 million raised in a series D financing last December, will help support the clinical trials needed to achieve that goal.

According to the company, it plans to launch new studies within the next month.

"With Roche's investment and expertise, we'll be able to further accelerate and augment the development of our platform to test for additional cancers, and expand our real-world data programs," Freenome CEO Mike Nolan said in a statement.

"We believe blood-based multimodal screening and data-driven medical insights will help deliver personalized healthcare. This investment will be an important step to advance early cancer screening, and we look forward to joining Freenome in this journey," added Roche Diagnostics CEO Thomas Schinecker.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.